Journey Medical Corporation Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

LICENSES ACQUIRED (Details)

LICENSES ACQUIRED (Details) $ in Thousands, ¥ in Billions					1 Months Ended				3 Months Ended	9 Months Ended
LICENSES ACQUIRED (Details) $ in Thousands, ¥ in Billions	Nov. 11, 2024 USD ($)	Aug. 31, 2023 USD ($)	Aug. 31, 2023 CNY (¥)	Jun. 29, 2021 USD ($)	Aug. 31, 2025 USD ($)	Jan. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Jul. 31, 2020 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2025 USD ($)
Assets and Licenses Acquired
Total other revenues									$ 606	$ 606
Amzeeq
Assets and Licenses Acquired
Percentage of license						4.00%
Zilxi
Assets and Licenses Acquired
Percentage of license						1.50%
Emrosi Agreement
Assets and Licenses Acquired
Total Upfront payment				$ 10,000
Upfront payment upon execution				3,000
Remaining upfront payment				15,000
Transformation of ownership and all assets of milestone payments				15,000
Threshold additional contingent regulatory and commercial milestone payments payable				$ 150,000
Percentage of reduction in royalty upon launching of competitor products				50.00%
Emrosi Agreement \| Minimum
Assets and Licenses Acquired
Percentage of royalties payable on net sales				10.00%
Emrosi Agreement \| Maximum
Assets and Licenses Acquired
Percentage of royalties payable on net sales				14.00%
Asset purchase agreement \| Qbrexza
Assets and Licenses Acquired
Age of patients							9 years
Asset purchase agreement \| Royalty payment percentage for first two years \| Qbrexza
Assets and Licenses Acquired
Period of royalty payments							2 years
Asset purchase agreement \| Minimum \| Royalty payment percentage for first two years \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments							30.00%
Asset purchase agreement \| Minimum \| Royalty payment percentage for thereafter \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments							12.00%
Asset purchase agreement \| Maximum \| Royalty payment percentage for first two years \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments							40.00%
Asset purchase agreement \| Maximum \| Royalty payment percentage for thereafter \| Qbrexza
Assets and Licenses Acquired
Percent of royalty payments							19.00%
Asset purchase agreement \| Eli Lilly and Company \| Qbrexza
Assets and Licenses Acquired
Upfront fees							$ 12,500
Milestone payments payable							$ 144,000
License and supply agreement With DRL \| Accutane
Assets and Licenses Acquired
Amount of expense agreed to pay under the agreement								$ 5,000
Contingent amount payable								$ 17,000
Term of accutane								10 years
Termination accutane agreement period								180 days
New License Agreement
Assets and Licenses Acquired
Total Upfront payment		$ 19,000
Amount of obligation payment terminated		10,000
Remaining obligation payments		$ 45,000
New License Agreement \| Net sales of at least ¥4 billion (yen)
Assets and Licenses Acquired
Net sales \| ¥			¥ 4
Cutia License Agreement \| Amzeeq
Assets and Licenses Acquired
Percentage of license					4.00%
Milestone payment	$ 1,000
Total other revenues	1,000				$ 600				$ 606	$ 606
Milestone payment received, net	$ 1,000
VYNE APA
Assets and Licenses Acquired
Total Upfront payment						$ 450,000
Upfront payment upon execution						5,000
Upfront fees						20,000
VYNE APA \| Amzeeq \| First year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement						10,000
Net sales						100,000
VYNE APA \| Amzeeq \| Second year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement						20,000
Net sales						200,000
VYNE APA \| Amzeeq \| Third year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement						30,000
Net sales						300,000
VYNE APA \| Amzeeq \| Fourth year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement						40,000
Net sales						400,000
VYNE APA \| Amzeeq \| Fifth year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement						50,000
Net sales						500,000
VYNE APA \| Zilxi \| First year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement						10,000
Net sales						100,000
VYNE APA \| Zilxi \| Second year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement						20,000
Net sales						200,000
VYNE APA \| Zilxi \| Third year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement						30,000
Net sales						300,000
VYNE APA \| Zilxi \| Fourth year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement						40,000
Net sales						400,000
VYNE APA \| Zilxi \| Fifth year anniversary
Assets and Licenses Acquired
Amount of expense paid under the agreement						50,000
Net sales						$ 500,000